SYP-5

Research use only, not for human use.

A novel potent HIF-1 inhibitor that inhibits hypoxia-induced upregulation of HIF-1.

A novel potent HIF-1 inhibitor that inhibits hypoxia-induced upregulation of HIF-1, suppresses tumor cells invasion and angiogenesis; down-regulates VEGF and MMP-2, suppresses angiogenesis induced by hypoxia and VEGF in vitro; inhibits tumor cell migration and invasion by suppressing PI3K/AKT- and MAPK/ERK-dependent HIF-1 pathway.

SYP-5 inhibits hypoxia-induced upregulation of HIF-1. SYP-5 inhibits HIF-1 and downstream gene expression in Hep3B and Bcap37 cells. SYP-5 inhibits tumor cell migration and invasion, as well as tumor angiogenesis, which are mediated by suppressing PI3K/AKT- and MAPK/ERK-dependent HIF-1 pathway. The proteins of vascular endothelial growth factor (VEGF) and matrix metalloproteinases (MMP)-2 that are targets of HIF-1, are down-regulated by SYP-5. SYP-5 displays significant inhibition on hypoxia-induced overexpression of VEGF and MMP2 in both cell lines. In the tube formation assay, SYP-5 suppresses angiogenesis induced by hypoxia and VEGF in vitro. SYP-5 also retards the Hep3B and Bcap37 cells migration and invasion induced by hypoxia and FBS. SYP-5 specifically inhibits hypoxic induction of luciferase expression in U251-HRE but not in U251-pGL3.

——

SYP5 | SYP 5

Angiogenesis

HIF/HIF Prolyl-hydroxylase

HIF/HIF Prolyl-hydroxylase

Cancer

——

1384268-04-5

312.3828

C18H16O3S

>98% (HPLC)

10 mM in DMSO

CC1(C=CC2=C(O1)C=CC(=C2O)C(=O)C=CC3=CC=CS3)C

2-Propen-1-one, 1-(5-hydroxy-2,2-dimethyl-2H-1-benzopyran-6-yl)-3-(2-thienyl)-, (2E)-

(-20℃)

With Ice Pack

≥ 2 years